Table 2.

Comparisons between patients post–allo-HCT and post–auto-HCT to healthy controls

Anti–SARS-CoV-2 spike IgG, median (IQR)PNeutralizing Abs, median (IQR)P
Healthy (N = 54)All cellular treatments (N = 217)Healthy (N = 21)All cellular treatments (N = 180)
7,720 (3,885–9,746)3,292.7 (456.9–15,600.2)0.00195.8 (94.5–96.3)89.1 (39.1–96.2)0.007
Allo-HCT (N = 149)Allo-HCT (N = 122)
5,019.8 (635.4–15,914.5)0.02490 (41.7–96.3)0.025
Early allo (N = 19)Early allo (N = 14)
445.6 (112.3–5,728.2)<0.00174.9 (12.3–95.7)0.023
Mid-allo (N = 55)Mid-allo (N = 49)
3,409.3 (683.8–20,901.2)0.02788.5 (46.5–96.3)0.053
Late allo (N = 75)Late allo (N = 61
6,786.6 (1,833.5–17,535.7)0.43494.6 (60.3–96.3)0.172
Auto-HCT (N = 61)Auto-HCT (N = 52)
2,260.1 (419.4–10,598.8)<0.00179.8 (33.9–96.2)0.002
Early auto (N = 20)Early auto (N = 15)
718 (16.1–6,300.1)0.00144.8 (0–83.2)<0.001
Late auto (N = 41)Late auto (N = 37)
2,512.3 (673–10,598.8)0.00585.9 (52.3–96.3)0.009
  • NOTE: Early allo, <1 year; mid-allo, 1–3 years; late allo >3 years; early auto, <1 year; late auto, >1 year.